Baricitinib 4 mg (Barigen)

Baricit 4 mg is indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of Baricit 4 mg in combination with other JAK inhibitors ... Read more: Baricit 4 mg is indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of Baricit 4 mg in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. Therapeutic Class Immunosuppressant Pharmacology Baricit 4 mg is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis a...